Project/Area Number |
10470187
|
Research Category |
Grant-in-Aid for Scientific Research (B).
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Dermatology
|
Research Institution | Hamumatsu University School of Medicine |
Principal Investigator |
TAKIGAWA Masahiro Dermatology, Hamumatsu University School of Medicine, Professor, 医学部, 教授 (80115873)
|
Co-Investigator(Kenkyū-buntansha) |
SEO Haohiro Dermatology, Hamumatsu University School of Medicine, Assistant, 医学部, 助手 (50283354)
|
Project Period (FY) |
1998 – 2000
|
Project Status |
Completed (Fiscal Year 2000)
|
Budget Amount *help |
¥11,900,000 (Direct Cost: ¥11,900,000)
Fiscal Year 2000: ¥4,200,000 (Direct Cost: ¥4,200,000)
Fiscal Year 1999: ¥3,700,000 (Direct Cost: ¥3,700,000)
Fiscal Year 1998: ¥4,000,000 (Direct Cost: ¥4,000,000)
|
Keywords | CTL / fumor cell / Langerhans cell / barrier-disruption / tape-stripping / 腫瘍抗原ペプチド / 腫瘍免疫 / ワクチン / 抗原ペプチド / 皮膚 / 角質層 / バリア破壊 / 癌抗原ペプチド / 癌免疫治療 / 癌ワクチン |
Research Abstract |
H-2K^b-restricted tumor epitope peptides, including tyrosinase-related protein 2 residues 181-188 (TRP-2) and connexin 37 residues 52-59 (MUT1), were applied to permeability barrier-disrupted C57BL/6 (B6) mouse skin from which the stratum corneum of the epidermis had been removed by tape-stripping. This procedure primed tumor-specific cytotoxic T lymphocytes (CTLs) in the lymph nodes and spleen, protected mice against subsequent challenge with corresponding tumor cells, and suppressed the growth of established tumors. Preventive and therapeutic effectiveness was correlated with the frequency of tumor-specific CTL precursors. MHC class II la^<b+> cells separated from tape-stripped skin, compared with those from intact skin, exhibited a strong antigen-presenting capacity for CTL, suggesting that CTL expansion after peptide application is primarily mediated by epidermal Langerhans cells. Thus, percutaneous peptide immunization via barrier-disrupted skin provides a simple and noninvasive means of inducing potent anti-tumor immunity which may be exploited for cancer immunotherapy.
|